alteplase – Medxy AI

Tenecteplase Efficacy in Distal Cerebral Artery Occlusions: Insights From the Secondary Analysis of the TASTE Randomized Clinical Trial

By MedXY 09/09/2026

Secondary analysis of the TASTE trial reveals tenecteplase confers superior functional outcomes versus alteplase in patients with distal middle cerebral artery occlusions, supporting its use in more peripheral ischemic stroke territories.

Critical Care Neurology news

Body Weight and Alteplase Efficacy in Acute Ischemic Stroke: Insights from the ENCHANTED Trial

By MedXY 08/28/2026

The ENCHANTED trial post hoc analysis reveals body weight does not alter alteplase dose effectiveness in acute ischemic stroke, but low body weight independently predicts poorer outcomes without increased hemorrhagic risk.

Neurology news

Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial

By MedXY 06/03/2026

In a randomized trial of large-vessel-occlusion stroke, standard-dose tenecteplase improved early reperfusion before thrombectomy compared with low-dose alteplase, with similar safety and functional outcomes.

Neurology news

Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial

By MedXY 06/03/2026

In patients with large-vessel-occlusion stroke undergoing thrombectomy, standard-dose tenecteplase achieved more early reperfusion than low-dose alteplase, with similar safety and functional outcomes.

Clinical Updates Neurology news

Optimizing Prehospital Pathways: Impact of the Iranian Comprehensive Code Stroke Management Program (ICSM Phase III) on Thrombolysis Rates

By MedXY 03/11/2026

This review analyzes the ICSM Phase III study, highlighting how a structured empowerment program and standardized protocols in EMS significantly reduced prehospital delays and tripled alteplase administration rates for acute ischemic stroke.

Neurology news

Bridging IV Alteplase Before EVT Modestly Raises Intracranial Hemorrhage Risk — But Net Clinical Impact Is Complex

By MedXY 12/11/2025

An IPD meta-analysis of six randomized trials (2313 patients) found IV alteplase before EVT modestly increased intracranial hemorrhage—particularly parenchymal hematoma—yet ICH risk must be balanced against IVT-associated improvements in reperfusion and potential clinical benefit.

Neurology news

Evaluating Alteplase Use in Minor Ischemic Stroke: Insights from a Nationwide Chinese Registry

By MedXY 10/29/2025

A nationwide Chinese registry analysis reveals no overall benefit of intravenous alteplase in minor ischemic stroke but suggests select subgroups, especially those with disabling symptoms or higher NIHSS scores, may experience improved functional outcomes.

Ophthalmology Specialties

Intravenous Alteplase Versus Oral Aspirin in Acute Central Retinal Artery Occlusion: Insights from the THEIA Phase 3 Trial and Contextual Evidence

By MedXY 10/22/2025

THEIA trial evaluated intravenous alteplase against oral aspirin in acute CRAO within 4.5 hours; no significant visual improvement difference was found, emphasizing the need for further research and meta-analyses to clarify thrombolysis benefits.

Neurology news Specialties

Extending the Therapeutic Window: Alteplase Use 4.5 to 24 Hours After Ischemic Stroke in the HOPE Trial

By MedXY 09/03/2025

The HOPE trial demonstrates that intravenous alteplase administered 4.5 to 24 hours after ischemic stroke onset improves functional independence in patients with salvageable brain tissue, despite increased risk of symptomatic intracranial hemorrhage.

Clinical Updates Neurology news Specialties

JAMA: Extending Intravenous Alteplase to 24 Hours in Imaging‑Selected Ischemic Stroke (HOPE Trial)

By MedXY 08/10/2025

The HOPE randomized trial shows that CT‑perfusion–selected patients treated with intravenous alteplase at 4.5–24 hours (no planned thrombectomy) had higher 90‑day functional independence (40.3% vs 26.3%), with increased symptomatic intracranial hemorrhage but no higher mortality.